Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$981.66M
Gross Margin
97.19%
TTM Avg
61.28%
3Y Avg
80.64%
5Y Avg
87.09%
Market Cap
$973.93M
Gross Margin
79.21%
TTM Avg
77.54%
3Y Avg
74.46%
5Y Avg
74.10%
Market Cap
$982.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$996.65M
Gross Margin
63.74%
TTM Avg
62.39%
3Y Avg
56.59%
5Y Avg
42.69%
Market Cap
$998.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$953.81M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 97.19% | 61.28% | 80.64% | 87.09% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 79.21% | 77.54% | 74.46% | 74.10% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 63.74% | 62.39% | 56.59% | 42.69% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.00% | 0.00% | 0.00% | 16.67% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 100.00% | 100.00% | 50.00% | 50.00% |
| Savara Inc. (SVRA)vs › | $952.91M | 0.00% | 0.00% | 0.00% | -2255.58% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
